Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O14494

UPID:
PLPP1_HUMAN

ALTERNATIVE NAMES:
Lipid phosphate phosphohydrolase 1; PAP2-alpha; Phosphatidate phosphohydrolase type 2a; Phosphatidic acid phosphatase 2a

ALTERNATIVE UPACC:
O14494; B7ZKN8; G3XA95; O60457; O60463; Q17RZ4

BACKGROUND:
Phospholipid phosphatase 1, with aliases including PAP2-alpha and Phosphatidate phosphohydrolase type 2a, is a magnesium-independent enzyme crucial for the metabolism of glycerolipid and sphingolipid phosphate esters. It facilitates the extracellular hydrolysis and cellular uptake of lipid mediators, thereby influencing signal transduction pathways essential for cell function.

THERAPEUTIC SIGNIFICANCE:
The strategic exploration of Phospholipid phosphatase 1's function offers a promising avenue for drug discovery. Given its essential role in the regulation of inflammation, platelet activation, and cell migration, targeting this enzyme could lead to innovative treatments for conditions characterized by these pathological processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.